Effect of Valsartan on N-Terminal Pro-Brain Natriuretic Peptide in Patient With Stable Chronic Heart Failure: Comparison With Enalapril
| Autor: | Ji Yong Choi, Sung Gug Chang, Geu Ru Hong, Seung Ho Hur, Jae Kean Ryu, Byung Chun Jung, Young Dae Kim, Tae Ik Kim, Kee Sik Kim, Young Soo Lee, Dong-Soo Kim, Jin Bae Lee, Bong Ryeol Lee, Tae Ho Park, Byung Soo Kim, Byong-kyu Kim |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
Congestive heart failure
medicine.medical_specialty Angiotensin receptor medicine.drug_class Pharmacology Internal medicine Renin–angiotensin system Angiotensin-converting enzyme inhibitors Internal Medicine Natriuretic peptide medicine Enalapril cardiovascular diseases Angiotensin receptor blocker biology business.industry Angiotensin-converting enzyme medicine.disease Brain natriuretic peptide Endocrinology Valsartan Heart failure biology.protein Original Article Cardiology and Cardiovascular Medicine business hormones hormone substitutes and hormone antagonists medicine.drug circulatory and respiratory physiology |
| Zdroj: | Korean Circulation Journal |
| ISSN: | 1738-5555 1738-5520 |
| Popis: | Background and Objectives The plasma concentration of N-terminal pro-brain natriuretic peptide (NT-pro-BNP) is a st-rong prognostic indicator for patients with heart failure (HF) across all stages of the condition. Several clinical trials have de-monstrated convincingly that neurohormonal modulation on the renin angiotensin system (RAS) decreases plasma NT-pro-BNP level and results in favorable outcomes. But there are still limited comparative data on the neuro-hormonal modulatory effects of two RAS inhibitors: angiotensin converting enzyme inhibitor and angiotensin receptor blocker. Subjects and Methods This study was a prospective, multi-center, randomized, open-label, controlled, and non-inferiority study involving 445 patients with left ventricular ejection fraction (LVEF) less than 45%. Patients were assigned to receive either valsartan (target dose of 160 mg bid) or enalapril (target dose of 10 mg bid) for 12 months. We compared plasma NT-pro-BNP, high sensitive C-reactive protein (hs-CRP) level and echocardiographic parameters before and after treatment with valsartan or enalapril. Results: The NT-pro-BNP and hs-CRP levels were significantly decreased after 12 months of treatment with valsartan and enalapril. The percentage change was similar between both groups. LVEF improved and left ventricular internal dimensions were decreased in both groups, and there were no significant differences between two groups. Conclusion Valsartan is as effective on improving plasma NT-pro-BNP level as enalapril in patients with stable chronic HF. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|